Eli Lilly Alzheimer’s hopes overdone? | Lex
- 5 years ago
► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs
Lex on whether 26% share climb is overly optimistic
Shares in Eli Lilly had already risen 26% ahead of an announcement today about its hopes for its Alzheimer’s treatment. Lex's Richard Stovin-Bradford and Alan Livsey discuss whether the stock climb is overdone.
► Lex: http://bit.ly/1I14JZF
► FT Business: http://bit.ly/1KUK08s
For more video content from the Financial Times, visit http://www.FT.com/video
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes
Lex on whether 26% share climb is overly optimistic
Shares in Eli Lilly had already risen 26% ahead of an announcement today about its hopes for its Alzheimer’s treatment. Lex's Richard Stovin-Bradford and Alan Livsey discuss whether the stock climb is overdone.
► Lex: http://bit.ly/1I14JZF
► FT Business: http://bit.ly/1KUK08s
For more video content from the Financial Times, visit http://www.FT.com/video
Twitter https://twitter.com/ftvideo
Facebook https://www.facebook.com/financialtimes